Aura Biosciences to Present Two Year Phase 1b/2 Clinical Data for AU-011 at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting

Aura Biosciences announced that two year clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the primary treatment of primary choroidal melanoma, will be highlighted in a poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting being held April 28-May 2, 2019, in Vancouver, British Columbia.

Aura Biosciences to Present Interim Phase 1b/2 Clinical Data for AU-011 at the International Society of Ocular Oncology 2019 Annual Meeting

Aura Biosciences today announced that interim clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the primary treatment of primary choroidal melanoma, will be highlighted in an oral presentation at the International Society of Ocular Oncology (ISOO) 2019 Annual Meeting being held March 22-26, 2019, in Los Angeles.

Aura Biosciences to Present at Upcoming Investor Conferences

Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that management will present a company overview at the following investor conferences: 

  • Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019, at 10:00 a.m. Eastern Time in Boston, MA

  • Oppenheimer's 29th Annual Healthcare Conference on Tuesday, March 19, 2019, at 9:10 a.m. Eastern Time in New York, NY

Aura Biosciences Announces Successful Outcome of End of Phase 2 Meeting with FDA for AU-011 for the Treatment of Patients with Choroidal Melanoma

The company has received written confirmation from the U.S. Food and Drug Administration (FDA) regarding agreement on the design of its Phase 3 registration trials designed to evaluate light-activated AU-011 for the treatment of patients with choroidal melanoma.  This written confirmation is the result of successful outcome of an “End of Phase 2” meeting with the FDA.